Literature DB >> 18923523

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Isabelle Janoueix-Lerosey1, Delphine Lequin, Laurence Brugières, Agnès Ribeiro, Loïc de Pontual, Valérie Combaret, Virginie Raynal, Alain Puisieux, Gudrun Schleiermacher, Gaëlle Pierron, Dominique Valteau-Couanet, Thierry Frebourg, Jean Michon, Stanislas Lyonnet, Jeanne Amiel, Olivier Delattre.   

Abstract

Neuroblastoma, a tumour derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumours in childhood. It usually occurs sporadically but familial cases are observed, with a subset of cases occurring in association with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene. Here we conducted genome-wide comparative genomic hybridization analysis on a large series of neuroblastomas. Copy number increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was observed recurrently. One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development. Through subsequent direct sequencing of cell lines and primary tumour DNAs we identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots. Germline mutations were observed in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene. Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity. The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation. Altogether, these data identify ALK as a critical player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18923523     DOI: 10.1038/nature07398

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  342 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.

Authors:  Franck Bourdeaut; Sandrine Ferrand; Laurence Brugières; Marjorie Hilbert; Agnès Ribeiro; Ludovic Lacroix; Jean Bénard; Valérie Combaret; Jean Michon; Dominique Valteau-Couanet; Bertrand Isidor; Xavier Rialland; Maryline Poirée; Anne-Sophie Defachelles; Michel Peuchmaur; Gudrun Schleiermacher; Gaëlle Pierron; Marion Gauthier-Villars; Isabelle Janoueix-Lerosey; Olivier Delattre
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

3.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

4.  Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

Authors:  Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé
Journal:  Sci Transl Med       Date:  2011-11-09       Impact factor: 17.956

5.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.

Authors:  E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 6.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

Review 7.  Emerging importance of ALK in neuroblastoma.

Authors:  Anna M Azarova; Gargi Gautam; Rani E George
Journal:  Semin Cancer Biol       Date:  2011-09-16       Impact factor: 15.707

8.  ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.

Authors:  Johannes M Heuckmann; Michael Hölzel; Martin L Sos; Stefanie Heynck; Hyatt Balke-Want; Mirjam Koker; Martin Peifer; Jonathan Weiss; Christine M Lovly; Christian Grütter; Daniel Rauh; William Pao; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2011-09-26       Impact factor: 12.531

Review 9.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 10.  New insights into the genetics of neuroblastoma.

Authors:  Srishma Sridhar; Batool Al-Moallem; Hawra Kamal; Marta Terrile; Raymond L Stallings
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.